NCT00352898

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Comparative Study Evaluating the Immunogenicity & Safety of MeMuRu-OKA Vaccine & Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™) in Children Primed With Both Measles-mumps-rubella & Varicella Vaccines

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 400 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 15 Months – 6 Years
• Healthy volunteers: Accepted

Summary

Since measles-mumps-rubella (MMR) and varicella vaccinations are established as routine childhood practice and often co-administered during the second year of life, a combined measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine is fully justified. Such a combined vaccine was developed and extensively studied in susceptible children. In countries where varicella mass-vaccination is already implemented, a transition period is necessary as children who started with separate first-dose vaccinations of MMR and varicella will receive a single shot of the combined vaccine as the second dose. To account for those situations, this study will evaluate the effect of the combined measles-mumps-rubella-varicella vaccine given in place of separate MMR and varicella vaccines as a second dose.

Conditions

• Mumps
• Rubella
• Measles
• Varicella

Interventions

Type	Name	Description
BIOLOGICAL	MeMuRu-OKA (study vac)
BIOLOGICAL	MMR, Varicella vacc (control)

Timeline

• Start date: 2006-04-01
• Completion: 2006-11-01
• First posted: 2006-07-17
• Last updated: 2016-10-07

Locations

6 sites across 2 countries: Canada, Italy